辉瑞和Genmab宣布ADC TIVDAK®获美国FDA批准，用于治疗复发性或转移性宫颈癌-动脉橙

辉瑞和Genmab宣布ADC TIVDAK®获美国FDA批准，用于治疗复发性或转移性宫颈癌

2024-04-30 BioSpace 等4家媒体报道 FDA动态





Genmab A/S和辉瑞公司宣布，FDA已批准TIVDAK治疗化疗后进展的复发或转移性宫颈癌患者。该批准基于3期innovaTV 301试验，其中TIVDAK与化疗相比显示总体生存率提高。次要终点也得到了满足。TIVDAK是第一个获得FDA全面批准的具有总体生存数据的ADC，为这些患者提供了急需的治疗选择。（摘要由动脉网AI生成）

关联公司

 Genmabpfizer

2024-04-29 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

BioSpace
2024-04-29 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

GlobeNewswire
2024-04-29 TIVDAK ® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

businesswire
2024-04-30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Genmab